Topic 346: Targeted Radionuclide Therapy of Neuroendocrine Tumors Using 212Pb-octreotate Analogs

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 75N91018C00048-0-0-0
Agency Tracking Number: N44CA180048
Amount: $1,994,002.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: N/A
Timeline
Solicitation Year: 2017
Award Year: 2018
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
9701 Richmond Ave, HOUSTON, TX, 77042
DUNS: 782281302
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Izabela Tworowska
 (832) 868-2812
 itworowska@radiomedix.com
Business Contact
 Izabela Tworowska
Phone: (832) 868-2812
Email: itworowska@radiomedix.com
Research Institution
N/A
Abstract
A peptide receptor radionuclide therapy (PRRT) using [177Lu]/[90Y]-labeled somatostatin analogs has been proven to induce objective response in 30-45% of patients with advanced/progressive neuroendocrine tumors (NETs). The complete response to beta-emitter PRRT is rare. This is due to the fact that NETs are diagnosed at late stage of disease; the NETs patients with remissions could develop resistance to beta-radiation therapy that could be overcome by alpha-emitter-targeted-therapy (TAT). The commercial potential of TAT has been confirmed by recent introduction of Xofigo for therapy of bone metastasis in prostate cancer; and remissions of NETs in patients undergoing therapy with [213Bi]DOTATOC and [225Ac]DOTA-TATOC. The TAT has a potential to revolutionize treatment of NETs whether applied alone or supported by beta-emitter PRRT. It can significantly enhance therapeutic efficacy of PRRT without side effects on non-targeted normal tissues. Our Phase I Contract produced favorable results of the pre-clinical efficacy, long term-toxicity and dosimetry studies [212Pb]-octreotate. These results together with the safety, and dosimetry of 203Pb-octreotate in human allow us to propose the following objectives for the Phase II Contract: 1) Manufacturing of the clinical doses of [212Pb]-octreotate; (2) Initiation of Phase I dose escalation clinical studies of [212Pb]-octreotate in NETs patients. With success in these aims, we expect to a) evaluate our bussiness model of centralized production of clinical doses of [212Pb]-octreotate; b) assess the safety, and dose limiting toxicity of ascending doses of agent used for TAT of subjects with somatostatin receptor expressing NETs; c) determine the PK and the preliminary effectiveness of ascending doses of this drug.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government